Biotech Archives - Page 30 of 733

1 minute read

AstraZeneca’s COVID-19 Prevention Therapy Cuts Risk Of Infection In Patients With Weaker Immunity, Data Shows

May 16, 11:34 AM

AstraZeneca's Phase 3 SUPERNOVA trial shows sipavibart significantly reduces symptomatic COVID-19 in immunocompromised patients. The trial met primary endpoints, showing effectiveness against various SARS-CoV-2 variants.

AZN

1 minute read

‘PDS Biotech’s Survival Benefit Is Absurdly Overstated’ – By Adam Feuerstein/ STAT News

By Benzinga Newsdesk

May 16, 11:03 AM

https://www.statnews.com/2024/05/16/pds-biotech-survival-benefit/ This is the online edition of Adam's Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it

PDSB

1 minute read

Bristol Myers Squibb Presents New 4-Year Sotyktu Data Demonstrate Durable Response Rates And Consistent Safety In Moderate-To-Severe Plaque Psoriasis

By Benzinga Newsdesk

May 16, 10:26 AM

Following four years of continuous Sotyktu treatment, clinical response was maintained in more than seven out of 10 patients for Psoriasis Area and Severity Index (PASI) 75 in the POETYK PSO long-term extension trialNo

BMY

2 minute read

Eli Lilly’s Weekly Insulin Dose On Par With Commonly Used Daily Doses, Phase 3 Studies Show

By Vandana Singh

May 16, 10:13 AM

Eli Lilly phase 3 trials reveal once-weekly insulin efsitora as a non-inferior alternative to daily basal insulins for type 2 diabetes.

LLY

1 minute read

Southeastern Pennsylvania Transportation Authority Launches 3D Fare Gates Pilot Program With Conduent Transportation

By Benzinga Newsdesk

May 16, 8:49 AM

SEPTA pilots Conduent's solution with plans to expand the number of fare gates in the futureConduent's 3D Fare Gate Solution is designed to detect, deter and quantify fare evasion, benefiting both agencies and

CNDT

1 minute read

BullFrog AI And The Lieber Institute For Brain Development Collaborates To Identify Novel Drug Targets For Neuropsychiatric Disorders

By Benzinga Newsdesk

May 16, 8:18 AM

BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)))) ("BullFrog AI" or the "Company"), a technology-enabled drug discovery company using artificial intelligence (AI) and machine learning to enable the successful discovery

BFRG

1 minute read

Apogee Doses First Patient In Phase 2 Atopic Dermatitis Trial Of APG777 For The Treatment Of Atopic Dermatitis And Other Inflammatory Diseases

By Benzinga Newsdesk

May 15, 4:18 PM

Interim clinical data from APG777 Phase 1 healthy volunteers study exceeded all trial objectives and achieved a half-life of approximately 75 days with a potentially best-in-class profile 16-week proof-of-concept

APGE

2 minute read

Galapagos And Blood Centers Of America Collaborate To Expand Galapagos’ Decentralized CAR-T Manufacturing Network In The U.S.

By Benzinga Newsdesk

May 15, 4:03 PM

BCA's national network of blood centers will provide decentralized manufacturing services for Galapagos' CAR-T product candidates, close to cancer treatment centersCollaboration enables rapid deployment of Galapagos'

GLPG

2 minute read

Takeda’s Dengue Vaccine Gets WHO Approval, Eligible for UN Procurement

By Vandana Singh

May 15, 2:02 PM

Takeda's dengue vaccine, Qdenga, gains WHO prequalification, enabling UN agency procurement. Approved in multiple countries, Qdenga is recommended for children 6-16 in high dengue areas.

SNY

1 minute read

Phio Pharmaceuticals Completes Dosing In First Patient Cohort In PH-762 Phase 1b Dose-Escalation Study

By Benzinga Newsdesk

May 15, 1:02 PM

-PH-762 is Phio's lead product candidate -Screening on the next cohort is on-goingMARLBOROUGH, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company

PHIO